Drug Profile


Alternative Names: UNII-00OLE78529; VX-765

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vertex Pharmaceuticals
  • Class Aminobenzoic acids; Antipsoriatics; Dipeptides; Small molecules
  • Mechanism of Action Caspase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Cardiovascular disorders; Epilepsy; Inflammation; Psoriasis

Most Recent Events

  • 31 Dec 2011 Vertex Pharmaceuticals initiates enrolment in a Phase-IIb trial for treatment-resistant epilepsy in USA (NCT01501383)
  • 02 Dec 2011 Adverse events and efficacy data from a phase II trial in Epilepsy presented at the 65th Annual Meeting of the American Epilepsy Society (AES-2011)
  • 10 Mar 2011 Efficacy and adverse events data from a phase II trial in Partial epilepsies released by Vertex Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top